You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Ultraviolet-C Therapy for Onychomycosis

    SBC: KERADERM, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Keraderm LLC and the Wellman Center for Phototherapy propose a radically new treatment for onychomycosis using germicidal radiation instead of current medications which have significant drawbacks. Onychomycosis is a fungal nail infection that affects approximately 30 million Americans. Americans spend more than $1 Billion per year to treat this problem. However ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  2. Ultraviolet Light Devices for Vitamin D

    SBC: APOLLO LIGHT SYSTEMS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Vitamin D deficiency is now recognized as a significant health problem for middle-aged and older adults. Vitamin D deficiency exacerbates osteoporosis and causes the bone disease, osteomalacia. Vitamin D deficiency increases risk of skeletal fractures. It is well known that the ultraviolet B portion of the solar spectrum is responsible for the cutaneous product ...

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  3. Unbiased longitudinal neuromorphometry for clinical decision support

    SBC: CORTICOMETRICS LLC            Topic: NIA

    Project Summary Normal human neuroanatomy is incredibly variableand increases with ageThis impedes the ability of neuroimaging to detect effects in neurological conditions such as Alzheimerandapos s diseaseADHuntingtonandapos s diseaseHDmultiple sclerosisMSand schizophreniaMost of the recently available state of the art quantitative imaging tools still use cross sectional methods to analyze repeat ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Unbiased longitudinal neuromorphometry for clinical decision support

    SBC: CORTICOMETRICS LLC            Topic: NIA

    Project Summary Normal human neuroanatomy is incredibly variable, and increases with age. This impedes the ability of neuroimaging to detect effects in neurological conditions such as Alzheimerandapos;s disease (AD), Huntingtonandapos;s disease (HD), multiple sclerosis (MS) and schizophrenia. Most of the recently available state-of-the-art quantitative imaging tools still use cross-sectional metho ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Urine Diagnostics for Aspergillosis

    SBC: PEARL DIAGNOSTICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Aspergillosis is a severe fungal infection that most frequently involves the lungs in people who have immune deficiency caused by cancer chemotherapy and or transplantation Although good drugs are available establishing a diagnosis is difficult and late treatment has limited our progress in decreasing morbidity and mortality We observed that Aspergillus pol ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Urine Diagnostics for Aspergillosis

    SBC: PEARL DIAGNOSTICS, INC.            Topic: NIAID

    Invasive aspergillosisIAcontinues to cause morbidity and death in medically immune compromised patientslargely because we lack sensitive diagnostic tests that are easy to use during high risk periodsWe discovered that fungal galactofuranose containing antigens are excreted in urine of infected animals and peopleusing a novel monoclonal antibodymAbIn a phase I STTRwe engineered a lateral flow devic ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Urocortin-2 Gene Transfer for CHF: a Paracrine Approach Using Intravenous AAV8

    SBC: Renova Therapeutics, Inc.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Gene transfer for the treatment of cardiovascular diseases is bedeviled by inability to obtain, safely and easily, sufficient cardiac transgene expression. Current methods of gene transfer for heart disease include intramuscular injection into heart muscle or intracoronary delivery, approaches that are cumbersome to apply. Consequently, we have considered the u ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Urocortin Gene Transfer for CHF a Paracrine Approach Using Intravenous AAV

    SBC: Renova Therapeutics, Inc.            Topic: NHLBI

    DESCRIPTION provided by applicant Gene transfer for the treatment of cardiovascular diseases is bedeviled by inability to obtain safely and easily sufficient cardiac transgene expression Current methods of gene transfer for heart disease include intramuscular injection into heart muscle or intracoronary delivery approaches that are cumbersome to apply Consequently we have considered the u ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Urocortin-2 Gene Transfer for Type 1 Diabetes and Associated LV Dysfunction

    SBC: Renova Therapeutics, Inc.            Topic: NHLBI

    ABSTRACT TypeDiabetes MellitusT DMaffectsmillion patients in US withnew patients annuallyLifespan is shortenedyearsdue to kidney and heart diseaseTight glucose control reduces microvascular complications and adverse cardiovascular eventsInsulin therapy is essential for such patientsbut has shortcomingsaonlyinpatients achieve targeted glucose controlHbA c andltbaggressive insulin therapy increases ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Urocortin-2 Gene Transfer for Type 1 Diabetes and Associated LV Dysfunction

    SBC: Renova Therapeutics, Inc.            Topic: NHLBI

    ABSTRACT Type-1 Diabetes Mellitus (T1DM) affects 1.25 million patients in US with 40,000 new patients annually. Lifespan is shortened 11-13 years, due to kidney and heart disease. Tight glucose control reduces microvascular complications and adverse cardiovascular events. Insulin therapy is essential for such patients, but has shortcomings: a) only 1 in 3 patients achieve targeted glucose control ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government